Wei Hong

482 total citations
21 papers, 250 citations indexed

About

Wei Hong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wei Hong has authored 21 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Wei Hong's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (3 papers). Wei Hong is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Cancer therapeutics and mechanisms (3 papers). Wei Hong collaborates with scholars based in China and Hong Kong. Wei Hong's co-authors include Xinmin Yu, Xun Shi, Xiangyu Jin, Yan Sun, Jun Zhao, Kai Wang, Lei Shi, Dinghong Wu, Ning Li and Fuda Xie and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and FEBS Letters.

In The Last Decade

Wei Hong

20 papers receiving 246 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wei Hong China 9 117 108 88 47 37 21 250
Alfonsus Johannes Maria van den Eertwegh Netherlands 10 181 1.5× 60 0.6× 102 1.2× 39 0.8× 77 2.1× 24 290
Ganjun Kang China 10 75 0.6× 66 0.6× 105 1.2× 49 1.0× 50 1.4× 21 296
Alexa J. Resler United States 9 126 1.1× 30 0.3× 75 0.9× 79 1.7× 56 1.5× 12 323
Benno Traub Germany 9 156 1.3× 48 0.4× 126 1.4× 54 1.1× 86 2.3× 20 307
Fenglin Cai China 10 57 0.5× 81 0.8× 159 1.8× 101 2.1× 13 0.4× 25 269
James F. Catroppo United States 6 66 0.6× 125 1.2× 62 0.7× 46 1.0× 12 0.3× 6 223
Mileka Gilbert United States 6 192 1.6× 96 0.9× 47 0.5× 90 1.9× 131 3.5× 13 416
Agnieszka Synowiec Poland 9 92 0.8× 54 0.5× 90 1.0× 52 1.1× 30 0.8× 21 316
S. L. Graziano United States 5 87 0.7× 125 1.2× 141 1.6× 43 0.9× 8 0.2× 8 283

Countries citing papers authored by Wei Hong

Since Specialization
Citations

This map shows the geographic impact of Wei Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Hong more than expected).

Fields of papers citing papers by Wei Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Hong. The network helps show where Wei Hong may publish in the future.

Co-authorship network of co-authors of Wei Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Wei Hong. A scholar is included among the top collaborators of Wei Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei Hong. Wei Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hong, Wei, et al.. (2024). Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients. Cancer Management and Research. Volume 16. 1205–1213.
2.
Fan, Yun, Hui Li, Zhiyu Huang, et al.. (2024). High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.. Journal of Clinical Oncology. 42(16_suppl). 2007–2007. 1 indexed citations
3.
Wang, Pingli, Yuping Li, Dongqing Lv, et al.. (2021). Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. Signal Transduction and Targeted Therapy. 6(1). 374–374. 9 indexed citations
4.
Zhang, Miaomiao, Ning Li, Jiangyong Gu, et al.. (2021). Rosmarinic acid protects mice from imiquimod induced psoriasis‐like skin lesions by inhibiting the IL‐23/Th17 axis via regulating Jak2/Stat3 signaling pathway. Phytotherapy Research. 35(8). 4526–4537. 41 indexed citations
5.
6.
Yu, Ying, Haiyang Wang, Lanxiang Liu, et al.. (2021). Proteomic Profiling of Lysine Acetylation Indicates Mitochondrial Dysfunction in the Hippocampus of Gut Microbiota-Absent Mice. Frontiers in Molecular Neuroscience. 14. 594332–594332. 17 indexed citations
7.
Li, Hui, et al.. (2019). Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. Cancer Chemotherapy and Pharmacology. 83(6). 1083–1090. 13 indexed citations
8.
9.
Hong, Wei, Hui Li, Xiangyu Jin, & Xun Shi. (2017). P1.07-053 Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study. Journal of Thoracic Oncology. 12(1). S729–S729. 5 indexed citations
10.
Qian, Yingying, Shoujie Chai, Zuyu Liang, et al.. (2014). KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. Molecular Cancer. 13(1). 176–176. 47 indexed citations
11.
12.
Sun, Yan, Xinmin Yu, Xun Shi, et al.. (2014). Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World Journal of Surgical Oncology. 12(1). 148–148. 28 indexed citations
13.
Shao, Lan, Wei Hong, Lei Zheng, et al.. (2014). [Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].. SHILAP Revista de lepidopterología. 17(5). 391–400. 3 indexed citations
14.
Hong, Wei, Baochai Lin, Beibei Zhang, Weimin Mao, & Yiping Zhang. (2014). [Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].. SHILAP Revista de lepidopterología. 17(4). 321–6. 4 indexed citations
15.
Zhao, Peng, Yiping Zhang, Ying‐Hui Zhu, et al.. (2013). Adenovirus‐mediated Interferon‐γ Gene Therapy Induced Human Pancreatic Carcinoma Capan‐2 Cell Apoptosis In Vitro and In Vivo. The Anatomical Record. 296(4). 604–610. 8 indexed citations
16.
Hong, Wei, Kai Wang, Yiping Zhang, et al.. (2013). Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. Journal of Zhejiang University SCIENCE B. 14(3). 207–215. 18 indexed citations
17.
Zheng, Lei, Baochai Lin, Zhengbo Song, et al.. (2013). [Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor].. SHILAP Revista de lepidopterología. 16(12). 632–8. 8 indexed citations
18.
Hong, Wei, et al.. (2012). Palatine tonsillar metastasis of lung cancer during chemotherapy.. Europe PMC (PubMed Central). 14 indexed citations
19.
Shao, Lan, Dan Su, Fajun Xie, et al.. (2012). Analysis of efficacy and survival of patients receiving second-line treatment for sensitive recurrent small-cell lung cancer. Tumori. 32(11). 892–898. 2 indexed citations
20.
Xie, Fajun, Peng Zhao, Wei Hong, et al.. (2012). The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemotherapy and Pharmacology. 69(6). 1443–1448. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alfonsus Johannes Maria van den Eertwegh Breakdown of academic impact, for papers by Ganjun Kang Breakdown of academic impact, for papers by Alexa J. Resler Breakdown of academic impact, for papers by Benno Traub Breakdown of academic impact, for papers by Fenglin Cai Breakdown of academic impact, for papers by James F. Catroppo Breakdown of academic impact, for papers by Mileka Gilbert Breakdown of academic impact, for papers by Agnieszka Synowiec Breakdown of academic impact, for papers by S. L. Graziano
Rankless by CCL
2026